You may have already spoken to doctors and done your own research, but as you or your loved one prepares to start treatment with Optune, you might be wondering what more you should know. Here are some things to keep in mind as you get started.
When you're ready to start treatment, nCompass will arrange for in-person training. At that appointment, an nCompass DSS will teach you and your caregivers how to use the device and how to properly place transducer arrays.
Many patients rely on family, friends, and/or outside caretakers to assist them on array change days. It’s a good idea to have anyone who will be helping you with array changes present at your treatment education meeting. That way, your caregivers will be able to meet your DSS and learn about the device and proper array placement.
Transducer arrays need to be applied directly to your scalp to work properly. Hair growth prevents the arrays from making good contact with your scalp.
If you’d like, you can wear a loose-knit wig, hat, or breathable head covering over the transducer arrays.
Transducer arrays need to be changed at least 2 times per week (every 4 days at most). If you find that you sweat a lot or that your hair grows quickly, you may need to change them more often. Watch this tutorial to learn how transducer arrays are applied.
Optune should be used for at least 18 hours a day to get the best response from treatment. Therapy can be delivered while you sleep.
Optune records how much time per day therapy is being delivered. A monthly compliance report is provided to your doctors, so they can discuss your treatment goals with you.
It’s important that you keep the device and arrays from getting wet. Your DSS will provide direction on how to protect the transducer arrays and device before bathing. You can learn more about what to do if Optune gets wet on our FAQ page.
You may be able to use Optune while you go about your daily routine at work, for some travel, and at social functions like family get-togethers. You will want to speak with your doctor about whether it is okay for you to continue working or to travel. nCompass can work with you to provide additional batteries or other accommodations to use Optune at your office or while traveling. See how other patients have incorporated Optune into their lives here.
1. Optune Patient Information and Operation Manual. Novocure 2016. 2. Optune Instructions For Use. Novocure 2016.
Learn how nCompass supports Optune users every step of the way.Discover nCompass
Watch the video
Optune is a wearable, portable, FDA-approved device indicated to treat a type of brain cancer called glioblastoma multiforme (GBM) in adult patients 22 years of age or older.
If you have newly diagnosed GBM, Optune is used together with a chemotherapy called temozolomide (TMZ) if:
If your tumor has come back, Optune can be used alone as an alternative to standard medical therapy if:
Optune is not for everyone. Talk to your doctor if you have:
Do not use Optune if you are pregnant or are planning to become pregnant. It is not known if Optune is safe or effective during pregnancy.
Optune should only be used after receiving training from qualified personnel, such as your doctor, a nurse, or other medical staff who have completed a training course given by Novocure™, the maker of Optune.
Most common side effects of Optune when used together with chemotherapy (temozolomide, or TMZ) were low blood platelet count, nausea, constipation, vomiting, tiredness, scalp irritation from the device, headache, seizure, and depression.
The most common side effects when using Optune alone were scalp irritation (redness and itchiness) and headache. Other side effects were malaise, muscle twitching, fall and skin ulcers.
Talk to your doctor if you have any of these side effects or questions.
Please click here to see the Optune Instructions For Use (IFU) for complete information regarding the device's indications, contraindications, warnings, and precautions.
Optune is intended as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM).